7 hours ago
1
AscentXmedia/E+ via Getty Images
Silo Pharma (NASDAQ:SILO) has entered into a service agreement with medical technology provider Resyca BV for a drug-device study of SPC-15, its lead asset for post-traumatic stress disorder (PTSD) treatment.
“This study is expected to provide the final necessary device data and
English (US) ·